{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:41:42Z","timestamp":1770475302352,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2524,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2001,8,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>There is widespread use of spironolactone in medical practice and the indications for its use well established and side effect profile well known. Herein, we present a case of drug\u2010induced hepatitis occurring in a 50\u2010year\u2010old woman using spironolactone for the treatment of androgenetic alopecia. Six weeks after commencement of spironolactone the patient became unwell, complained of an extensive itch, but no icterus or jaundice. Liver function tests found abnormally elevated bilirubin and enzymes levels. After withdrawal of spironolactone, the patient\u2019s symptoms resolved and liver function improved. To date, there has only been one other report of spironolactone\u2010induced hepatitis.<\/jats:p>","DOI":"10.1046\/j.1440-0960.2001.00510.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T11:27:35Z","timestamp":1047295655000},"page":"180-182","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Spironolactone\u2010induced hepatitis"],"prefix":"10.1111","volume":"42","author":[{"given":"Keng\u2010Ee","family":"Thai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney D","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_4_2_2","first-page":"63","article-title":"Antiandrogens: Spironolactone, flutamide, cyproterone acetate and gonadotrophin\u2010releasing hormone inhibitors.","volume":"8","author":"Dawber RPR.","year":"1998","journal-title":"Dermatol. Ther."},{"key":"e_1_2_4_3_2","unstructured":"MIMS Australia.Diuretics. In: Caswell A Jarvis V Dalton C Gagic V (eds).2000 MIMS Annual 24th edn. Sydney: MIMS Australia. 1999; 2\u2010108\u20139."},{"key":"e_1_2_4_4_2","unstructured":"DienstagJK&IsselbacherKJ.Chronic hepatitis. In: Fauci AS Braunwald E Isselbacher KJ Kasper DL Hauser SL Longo DL Jameson JL (eds).Harrison\u2019s Principles of Internal Medicine Vol. 2 14th edn. New York: McGraw\u2010Hill 1998; 1696\u2013704."},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996428"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-95-6-708"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01263103"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91225-7"},{"key":"e_1_2_4_9_2","doi-asserted-by":"crossref","unstructured":"MurphyBJ&CollinsBJ.Severe hepatitis and liver failure induced by cyproterone acetate.Aust. N.Z. J. Med.1996;26: 724.","DOI":"10.1111\/j.1445-5994.1996.tb02956.x"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020007"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1191\/096032799678839806"},{"key":"e_1_2_4_12_2","doi-asserted-by":"crossref","unstructured":"GomezJL DupontA CusanL TremblayM TremblayM LabrieF.Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): A case report.Am. J. Med.1992;92: 563\u20136.","DOI":"10.1016\/0002-9343(92)90756-2"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(96)00355-x"},{"key":"e_1_2_4_14_2","first-page":"465","article-title":"Acute cholestatic hepatitis secondary to flutamide therapy.","volume":"92","author":"Prattichizzo FA.","year":"1992","journal-title":"Am. J. Med."},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90373-5"},{"key":"e_1_2_4_16_2","unstructured":"CorreiaMA&CastagnoliN.Drug biotransformation. In: Katzung BG (ed.).Basic and Clinical Pharmacology 4th edn. East Norwalk: Appleton and Lange 1989; 41\u201350."},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(70)90283-2"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-0960.2001.00510.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-0960.2001.00510.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:53:25Z","timestamp":1697522005000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-0960.2001.00510.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8,9]]}},"alternative-id":["10.1046\/j.1440-0960.2001.00510.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-0960.2001.00510.x","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,9]]},"assertion":[{"value":"2008-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}